ALNY: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/bd04d7de-a91d-4be5-8350-431a97162b04/","filing_uuid":"bd04d7de-a91d-4be5-8350-431a97162b04","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/bd04d7de-a91d-4be5-8350-431a97162b04/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Sarah Egge","dt_posted":"2026-07-20T18:13:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Avenue, NW","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401104582,"url":"https://lda.gov/api/v1/registrants/401104582/","house_registrant_id":null,"name":"SPLITOAK STRATEGIES LLC","description":"Health care consulting","address_1":"300 New Jersey Avenue, NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARAH EGGE","contact_telephone":"+1 703-203-7992","dt_updated":"2026-07-30T12:56:37.934245-04:00"},"client":{"id":202097,"url":"https://lda.gov/api/v1/clients/202097/","client_id":90,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-11-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67714,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"KUEHL","last_name":"EGGE","suffix":null,"suffix_display":null},"covered_position":"1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction","new":false},{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":"1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}